Pfizer has reached a $5.4 billion deal to buy Global Blood Therapeutics, which makes a drug for sickle-cell disease
New York drugmaker to pay $68.50 a share for GBT, which sells a drug for sickle-cell disease and has two more in development
Pfizer has said it wants to add $25 billion in revenue from business-development moves like mergers and acquisitions by 2030.Updated Aug. 8, 2022 11:17 am ET Pfizer Inc. has agreed to buy Global Blood Therapeutics Inc. for $5.4 billion, in a deal that would give the big drugmaker a foothold in the treatment of sickle-cell disease.
Pfizer said Monday it would pay $68.50 a share in cash for Global Blood Therapeutics, which has one of the few approved treatments for sickle-cell disease. The Wall Street Journal reported Friday that the
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer in talks on $5 billion acquisition: mediaAmerican drugmaker Pfizer is close to a deal to purchase Global Blood Therapeutics, which manufactures a recently approved drug against sickle-cell anemia, for $5 billion, the Wall Street Journal has reported.
Read more »
Pfizer buying spree continues with $5.4B hematology dealPfizer is buying sickle cell drug maker Global Blood Therapeutics in an approximately $5.4 billion deal as it looks to accelerate growth after its revenue soared during the pandemic.
Read more »
Pfizer agrees to buy Global Blood Therapeutics in deal valued at $5.4 billion: WSJPfizer Inc. undefined has reached an agreement to buy Global Blood Therapeutics Inc. [s :gbt] in a deal valued at $5.4 billion, the Wall Street Journal...
Read more »
Political Ad Spend Boosts Tegna Revenues Ahead of $5.4B Private Equity TakeoverThe latest financial results come as the local TV giant awaits completion of a sale to two private equity firms in a deal that values the station owner at $5.4 billion in equity value.
Read more »
Pfizer agrees to buy Global Blood Therapeutics in deal valued at $5.4 billion: WSJPfizer Inc. undefined has reached an agreement to buy Global Blood Therapeutics Inc. [s :gbt] in a deal valued at $5.4 billion, the Wall Street Journal...
Read more »
Pfizer buying spree continues with $5.4B hematology dealPfizer is buying sickle cell drug maker Global Blood Therapeutics in an approximately $5.4 billion deal as it looks to accelerate growth after its revenue soared during the pandemic.
Read more »